Flamel Technologies S.A. (NASDAQ:AVDL) insider Greg J. Divis purchased 10,600 shares of the stock in a transaction dated Tuesday, September 12th. The shares were purchased at an average price of $9.32 per share, with a total value of $98,792.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $98,792. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Flamel Technologies S.A. (AVDL) opened at 9.42 on Friday. The stock’s 50 day moving average price is $9.03 and its 200 day moving average price is $9.82. The stock has a market capitalization of $377.59 million, a price-to-earnings ratio of 9.95 and a beta of 1.39. Flamel Technologies S.A. has a 52-week low of $8.14 and a 52-week high of $14.15.

Flamel Technologies (NASDAQ:AVDL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.14. The business had revenue of $46.30 million during the quarter, compared to the consensus estimate of $45.17 million. Flamel Technologies had a return on equity of 29.84% and a net margin of 21.13%. The firm’s revenue was up 19.0% on a year-over-year basis. On average, analysts forecast that Flamel Technologies S.A. will post $1.16 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/17/flamel-technologies-s-a-avdl-insider-buys-98792-00-in-stock.html.

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of Flamel Technologies during the 1st quarter worth $3,654,000. US Bancorp DE acquired a new stake in shares of Flamel Technologies during the 1st quarter worth $121,000. Acadian Asset Management LLC increased its holdings in shares of Flamel Technologies by 9.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock worth $18,444,000 after buying an additional 147,907 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in Flamel Technologies by 27.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock worth $464,000 after purchasing an additional 9,175 shares during the period. Finally, Trexquant Investment LP boosted its position in Flamel Technologies by 30.7% during the 2nd quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock worth $336,000 after purchasing an additional 7,169 shares during the period. Institutional investors and hedge funds own 69.09% of the company’s stock.

AVDL has been the subject of several research analyst reports. Zacks Investment Research upgraded Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 17th. Roth Capital set a $15.00 price target on Flamel Technologies and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Ladenburg Thalmann Financial Services raised their price target on Flamel Technologies from $27.00 to $30.00 in a research report on Thursday, September 7th. Finally, Langenberg & Company restated a “buy” rating and set a $30.00 price target (up from $27.00) on shares of Flamel Technologies in a research report on Thursday, September 7th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $19.83.

Flamel Technologies Company Profile

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Insider Buying and Selling by Quarter for Flamel Technologies (NASDAQ:AVDL)

Receive News & Stock Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related stocks with our FREE daily email newsletter.